Core Viewpoint - Elbit Systems Ltd. announced a public offering of 1,365,450 ordinary shares, all of which will be sold by the company, with a potential additional 15% option for underwriters [1][2][3] Group 1: Offering Details - The offering is made under an effective shelf registration statement on Form F-3 filed with the SEC on May 21, 2025, which became effective immediately [3] - The net proceeds from the offering will be used for general corporate purposes [1] - The ordinary shares are expected to be listed for trading on the Nasdaq Global Select Market [1] Group 2: Underwriters - BofA Securities, J.P. Morgan, Jefferies, and Morgan Stanley are engaged as joint book-running managers for the offering [2] Group 3: Company Overview - Elbit Systems is a leading global defense technology company, employing approximately 20,000 people across five continents [5][6] - The company reported revenues of $1.9 billion for the three months ended March 31, 2025, and has an order backlog of $23.1 billion as of that date [6]

Core Viewpoint - Senseonics Holdings, Inc. has initiated an underwritten public offering of its common stock, with a potential additional 15% of shares available for underwriters to purchase [1][2]. Group 1: Offering Details - The public offering is subject to market conditions and will be made under a "shelf" registration statement filed with the SEC [3]. - TD Cowen and Barclays are the joint book-running managers for the offering, with RBC Capital Markets and Lake Street acting as bookrunners [2]. - A preliminary prospectus supplement will be filed with the SEC and will be accessible on their website [3]. Group 2: Concurrent Private Placement - Abbott Laboratories has agreed to purchase up to $25 million of Senseonics' common stock in a separate private placement, contingent on the public offering's closing [4]. - The net proceeds from both the public offering and the concurrent private placement will be used to support the launch of Eversense 365, ongoing product development, and general corporate purposes [5]. Group 3: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems for diabetes management, with products like Eversense® 365 and Eversense® E3 [8]. - The company's CGM systems feature a small sensor that is implanted under the skin and communicates glucose data to a mobile app every 5 minutes [8].

Core Viewpoint - Silo Pharma, Inc. has announced a public offering of 3,333,338 shares of common stock at a price of $0.60 per share, along with associated warrants, aiming to raise approximately $2 million for general working capital purposes [1][2]. Group 1: Offering Details - The public offering includes 3,333,338 shares of common stock and two series of warrants (Series A-1 and Series A-2), each with an exercise price of $0.60 per share [1]. - The Series A-1 Warrants are exercisable upon issuance and will expire five years thereafter, while the Series A-2 Warrants will expire eighteen months after issuance [1]. - The closing of the offering is expected to occur on or about May 16, 2025, subject to customary closing conditions [1]. Group 2: Financial Aspects - The gross proceeds from the offering are expected to be approximately $2 million before deducting fees and expenses [2]. - The net proceeds will be used for general working capital purposes [2]. Group 3: Company Overview - Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases [5]. - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis [5]. - Research is conducted in collaboration with leading universities and laboratories [5].

Core Viewpoint - Exagen Inc. has announced a public offering of 3,350,000 shares of its common stock at a price of $5.25 per share, aiming to raise approximately $17.59 million before expenses [1]. Group 1: Offering Details - The offering consists of 3,350,000 shares, with gross proceeds expected to be $17,587,500 before deducting underwriting discounts and commissions [1]. - Exagen has granted underwriters a 30-day option to purchase an additional 502,500 shares under the same terms [1]. - The offering is expected to close on May 9, 2025, pending customary closing conditions [1]. Group 2: Underwriting and Registration - Canaccord Genuity is acting as the sole bookrunner for the offering [2]. - The public offering is made under a shelf registration statement on Form S-3, which was filed with the SEC on November 17, 2023, and declared effective on November 29, 2023 [3]. Group 3: Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focused on improving care for patients with chronic autoimmune conditions [5]. - The company's flagship product, AVISE® CTD, aids in the diagnosis of complex autoimmune diseases such as lupus and rheumatoid arthritis [5]. - Exagen emphasizes research, innovation, and patient-centered care in addressing autoimmune disease management challenges [5].

Core Viewpoint - Pasithea Therapeutics has successfully closed a public offering, raising a total of approximately $6.3 million, which will be utilized for various corporate purposes including ongoing research and clinical trials [1][4]. Group 1: Offering Details - The company closed a public offering of 3,571,428 shares of common stock at a price of $1.40 per share, along with Series C and Series D warrants [1][2]. - The Series C warrants have an exercise price of $1.40 and expire in five years, while the Series D warrants also have an exercise price of $1.40 and expire in 18 months [2]. - The total gross proceeds from the offering were $5.0 million, with additional proceeds of approximately $1.3 million from the exercise of Series D warrants [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated for general corporate purposes, including ongoing research, clinical trials, and the development of new technologies [4]. - The company plans to invest in or acquire synergistic companies and engage in licensing activities related to its current and future product candidates [4]. Group 3: Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for central nervous system disorders and RASopathies [7].

Core Viewpoint - Theriva Biologics announced a public offering of up to 6,818,180 shares of common stock and warrants, aiming to raise approximately $7.5 million for working capital and R&D purposes [1][2]. Group 1: Offering Details - The offering price is set at $1.10 per share and accompanying warrant, with warrants exercisable immediately and expiring five years from issuance [1]. - The closing of the offering is expected on or about May 8, 2025, pending customary closing conditions [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily be used for working capital and general corporate purposes, including research and development and manufacturing scale-up [2]. - The company may also consider using a portion of the proceeds for investments or acquisitions, although no commitments currently exist [2]. Group 3: Company Overview - Theriva Biologics is a clinical-stage company focused on developing therapeutics for cancer and related diseases, with a particular emphasis on high unmet medical needs [6]. - The company's lead candidates include VCN-01, SYN-004, and SYN-020, targeting various aspects of cancer treatment and microbiome protection [6].

Core Viewpoint - Palatin Technologies, Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $11.5 million, with potential additional proceeds of up to $11.5 million from the exercise of milestone-related warrants [1][3]. Group 1: Offering Details - The public offering includes 76,666,667 shares of common stock and Series F, G, and H warrants, priced at $0.15 per share [1][2]. - Series F Warrants have an exercise price of $0.30 per share, are immediately exercisable, and expire five years from the issuance date [2]. - Series G Warrants have an exercise price of $0.15 per share, are immediately exercisable, and expire either 24 months from issuance or at the end of the FDA Exercise Period [2]. - Series H Warrants will be issued upon the exercise of Series G Warrants, with an exercise price of $0.225 per share and expiring 24 months after issuance [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes, particularly for the development of the company's obesity program [3]. Group 3: Closing and Agents - The closing of the offering is expected around May 8, 2025, pending customary closing conditions [3]. - A.G.P./Alliance Global Partners is the lead placement agent, with Laidlaw & Company (UK) Ltd. as the co-placement agent [4]. Group 4: Company Overview - Palatin Technologies is focused on developing first-in-class medicines targeting the melanocortin receptor system, addressing significant unmet medical needs [7]. - The company's strategy includes developing products and forming marketing collaborations to maximize commercial potential [7].

Houston, May 06, 2025 (GLOBE NEWSWIRE) -- LyondellBasell (NYSE: LYB) announced today that LYB International Finance III, LLC, its wholly-owned subsidiary, priced a public offering (the “Offering”) of $500,000,000 aggregate principal amount of 6.150% Guaranteed Notes due 2035 (the “Notes”). The Notes will be fully and unconditionally guaranteed by LyondellBasell. The Offering is expected to close on May 15, 2025, subject to the satisfaction of customary closing conditions. The net proceeds of the Offering ar ...

Core Points - BriaCell Therapeutics Corp. announced a public offering of 3,066,666 units at a price of $4.50 per unit, aiming for gross proceeds of approximately $13.8 million [1][2] - Each unit consists of one common share (or Pre-Funded Warrant) and one Warrant, with the Warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXZ" [1] - The offering is expected to close on April 28, 2025, subject to customary closing conditions [2] - The net proceeds will be used for working capital, general corporate purposes, and advancing business objectives [3] - A registration statement related to the securities was filed with the SEC and became effective on April 24, 2025 [4] Company Information - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [6]

Core Viewpoint - Cue Biopharma, Inc. is initiating an underwritten public offering of its common stock and accompanying warrants, subject to market conditions, with no assurance on the completion or terms of the offering [1] Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of therapeutic biologics aimed at selectively engaging and modulating disease-specific T cells for cancer and autoimmune disease treatment [1][5] - The company utilizes its proprietary platform, Immuno-STAT™, designed to harness the immune system's potential by selectively modulating disease-specific T cells without broad systemic immune effects [5] Offering Details - Oppenheimer & Co. Inc. is the sole book-running manager for the offering, while Newbridge Securities Corporation serves as co-manager [2] - A shelf registration statement related to the offering was filed with the SEC on May 9, 2023, and declared effective on May 26, 2023 [3] Contact Information - Investor contact is Marie Campinell, Senior Director of Corporate Communications at Cue Biopharma [10]